Avecho Biotechnology (ASX:AVE) completed the treatment phase for the last patient required for the planned interim analysis of its pivotal third-phase insomnia trial evaluating its tocopheryl phosphate mixture-enhanced cannabidiol capsule, according to a Thursday filing with the Australian bourse.
The analysis is expected to provide the first indication of the product's efficacy profile, determine the number of participants needed for the final study, and support ongoing licensing discussions, the filing said.
Results are expected in late June, per the filing.